Compile Data Set for Download or QSAR
maximum 50k data
Found 18 Enz. Inhib. hit(s) with Target = 'Plasma kallikrein' and Ligand = 'BDBM416987'
TargetPlasma kallikrein(Homo sapiens (Human))
Biocryst Pharmaceuticals

US Patent
LigandPNGBDBM416987((+-)-N-(5-(1-amino-3-cyclopropyl-1-phenylpropyl)-2...)
Affinity DataKi:  25.1nMAssay Description:The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
Biocryst Pharmaceuticals

US Patent
LigandPNGBDBM416987((+-)-N-(5-(1-amino-3-cyclopropyl-1-phenylpropyl)-2...)
Affinity DataKi:  25.1nMAssay Description:The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
Biocryst Pharmaceuticals

US Patent
LigandPNGBDBM416987((+-)-N-(5-(1-amino-3-cyclopropyl-1-phenylpropyl)-2...)
Affinity DataKi:  25.1nMAssay Description:The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
Biocryst Pharmaceuticals

US Patent
LigandPNGBDBM416987((+-)-N-(5-(1-amino-3-cyclopropyl-1-phenylpropyl)-2...)
Affinity DataKi:  25.1nMAssay Description:The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
Biocryst Pharmaceuticals

US Patent
LigandPNGBDBM416987((+-)-N-(5-(1-amino-3-cyclopropyl-1-phenylpropyl)-2...)
Affinity DataKi:  25.1nMAssay Description:Plasma kallikrein activity assay. The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic s...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
Biocryst Pharmaceuticals

US Patent
LigandPNGBDBM416987((+-)-N-(5-(1-amino-3-cyclopropyl-1-phenylpropyl)-2...)
Affinity DataKi:  25.1nMAssay Description:The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
Biocryst Pharmaceuticals

US Patent
LigandPNGBDBM416987((+-)-N-(5-(1-amino-3-cyclopropyl-1-phenylpropyl)-2...)
Affinity DataKi:  25.1nMAssay Description:The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates. In these experiments, 2...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
Biocryst Pharmaceuticals

US Patent
LigandPNGBDBM416987((+-)-N-(5-(1-amino-3-cyclopropyl-1-phenylpropyl)-2...)
Affinity DataKi:  25.1nMAssay Description:The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates. In these experiments, 2...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
Biocryst Pharmaceuticals

US Patent
LigandPNGBDBM416987((+-)-N-(5-(1-amino-3-cyclopropyl-1-phenylpropyl)-2...)
Affinity DataKi:  25.1nMAssay Description:The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
Biocryst Pharmaceuticals

US Patent
LigandPNGBDBM416987((+-)-N-(5-(1-amino-3-cyclopropyl-1-phenylpropyl)-2...)
Affinity DataKi:  25.1nMAssay Description:The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
Biocryst Pharmaceuticals

US Patent
LigandPNGBDBM416987((+-)-N-(5-(1-amino-3-cyclopropyl-1-phenylpropyl)-2...)
Affinity DataKi:  25.1nMAssay Description:Plasma kallikrein activity assay. The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic s...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
Biocryst Pharmaceuticals

US Patent
LigandPNGBDBM416987((+-)-N-(5-(1-amino-3-cyclopropyl-1-phenylpropyl)-2...)
Affinity DataKi:  25.1nMAssay Description:Plasma kallikrein activity assay. The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic s...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
Biocryst Pharmaceuticals

US Patent
LigandPNGBDBM416987((+-)-N-(5-(1-amino-3-cyclopropyl-1-phenylpropyl)-2...)
Affinity DataKi:  25.1nMAssay Description:The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
Biocryst Pharmaceuticals

US Patent
LigandPNGBDBM416987((+-)-N-(5-(1-amino-3-cyclopropyl-1-phenylpropyl)-2...)
Affinity DataKi:  25.1nMAssay Description:The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
Biocryst Pharmaceuticals

US Patent
LigandPNGBDBM416987((+-)-N-(5-(1-amino-3-cyclopropyl-1-phenylpropyl)-2...)
Affinity DataIC50:  2.20nMAssay Description:Inhibition of purified human plasma kallikrein using H-D-Pro-Phe-Arg-pNA.2HCl as substrate measured after 3 mins by microplate reader analysisMore data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails PubMed
TargetPlasma kallikrein(Homo sapiens (Human))
Biocryst Pharmaceuticals

US Patent
LigandPNGBDBM416987((+-)-N-(5-(1-amino-3-cyclopropyl-1-phenylpropyl)-2...)
Affinity DataIC50:  2.20nMAssay Description:Inhibition of purified human plasma kallikrein using H-D-Pro-Phe-Arg-pNA.2HCl as substrate measured after 3 mins by microplate reader analysisMore data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails PubMed
TargetPlasma kallikrein(Homo sapiens (Human))
Biocryst Pharmaceuticals

US Patent
LigandPNGBDBM416987((+-)-N-(5-(1-amino-3-cyclopropyl-1-phenylpropyl)-2...)
Affinity DataIC50:  24nMAssay Description:Inhibition of endogenous human plasma kallikrein using Z-Phe-Arg-AMC.HCl as substrate measured after 5 mins by microplate reader analysisMore data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails PubMed
TargetPlasma kallikrein(Homo sapiens (Human))
Biocryst Pharmaceuticals

US Patent
LigandPNGBDBM416987((+-)-N-(5-(1-amino-3-cyclopropyl-1-phenylpropyl)-2...)
Affinity DataIC50:  24nMAssay Description:Inhibition of endogenous human plasma kallikrein using Z-Phe-Arg-AMC.HCl as substrate measured after 5 mins by microplate reader analysisMore data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails PubMed